Orally Administered Plant-Based Cancer Vaccines: Biological Rationale, Current Evidence, and Translational Barriers

Orally administered plant-based cancer vaccines combine recombinant antigen production, cell-wall-mediated bioencapsulation and mucosal delivery, offering a potentially scalable and non-invasive vaccination platform. However, these technological advantages do not necessarily translate into therapeutic antitumor immunity. Following oral administration, plant-made antigens must survive gastrointestinal transit, reach relevant antigen-presenting cells and undergo effective presentation, including MHC-I cross-presentation, while avoiding intestinal tolerance. These requirements are particularly challenging for self-derived tumor-associated antigens. This review critically examines plant-expression platforms, antigen and glycan engineering, gastrointestinal release, mucosal uptake, immune activation and translational requirements. The evidence is organized in a tiered framework distinguishing plant-contained cancer antigens administered orally from parenterally administered plant-made cancer antigens, plant-based oral vaccines targeting oncogenic or other infectious agents and expression-only studies. Direct evidence remains limited to small preclinical investigations. The only identified study reporting an in vivo tumor outcome provided proof of concept that oral administration of a plant-made cancer antigen delayed tumor outgrowth; however, it used a small prophylactic tumor-challenge design and did not establish an antigen-directed immune mechanism or demonstrate therapeutic efficacy against established disease. Further development will require standardized pharmaceutical formulations, quantitative potency assays, established-tumor models and evidence of cross-presentation, functional tumor-reactive T cells, tumor infiltration and survival benefit. Orally administered plant-based cancer vaccines could be investigated as booster or maintenance components of prespecified combination regimens, particularly in minimal residual disease, but this proposed role and their therapeutic efficacy remain unproven.

Authors

Institutions

Publication Details

Journal
Biomedicines
Published
2026-11-16
DOI
https://doi.org/10.3390/biomedicines14112646
Primary Topic
Transgenic Plants and Applications
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Orally Administered Plant-Based Cancer Vaccines: Biological Rationale, Current Evidence, and Translational Barriers

Claudia Curcio, Silvia Brugiapaglia, Emanuela Noris, Simona Intonti et al.
2 links
Biomedicines
Transgenic Plants and Applications
article

Orally Administered Plant-Based Cancer Vaccines: Biological Rationale, Current Evidence, and Translational Barriers

Claudia Curcio, Silvia Brugiapaglia, Emanuela Noris, Simona Intonti, Mojgan Ghasemi Falavarjani
article en

Abstract

Orally administered plant-based cancer vaccines combine recombinant antigen production, cell-wall-mediated bioencapsulation and mucosal delivery, offering a potentially scalable and non-invasive vaccination platform. However, these technological advantages do not necessarily translate into therapeutic antitumor immunity. Following oral administration, plant-made antigens must survive gastrointestinal transit, reach relevant antigen-presenting cells and undergo effective presentation, including MHC-I cross-presentation, while avoiding intestinal tolerance. These requirements are particularly challenging for self-derived tumor-associated antigens. This review critically examines plant-expression platforms, antigen and glycan engineering, gastrointestinal release, mucosal uptake, immune activation and translational requirements. The evidence is organized in a tiered framework distinguishing plant-contained cancer antigens administered orally from parenterally administered plant-made cancer antigens, plant-based oral vaccines targeting oncogenic or other infectious agents and expression-only studies. Direct evidence remains limited to small preclinical investigations. The only identified study reporting an in vivo tumor outcome provided proof of concept that oral administration of a plant-made cancer antigen delayed tumor outgrowth; however, it used a small prophylactic tumor-challenge design and did not establish an antigen-directed immune mechanism or demonstrate therapeutic efficacy against established disease. Further development will require standardized pharmaceutical formulations, quantitative potency assays, established-tumor models and evidence of cross-presentation, functional tumor-reactive T cells, tumor infiltration and survival benefit. Orally administered plant-based cancer vaccines could be investigated as booster or maintenance components of prespecified combination regimens, particularly in minimal residual disease, but this proposed role and their therapeutic efficacy remain unproven.

BiomedicinesVol. 14(11)
Institute for Sustainable Plant Protection (IT), National Research Council (IT), University of Turin (IT)
Good health and well-being
Transgenic Plants and Applications
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon